Iovance generated Q4 2025 total product revenue of 86771000, reflecting approximately 30% sequential growth, with gross margin of approximately 50%. Net loss for the quarter was 71904000 as the company continued investing in commercialization and R&D.

Iovance Biotherapeutics reported strong product revenue growth in Q2 2025, primarily driven by the U.S. launch of Amtagvi, which surpassed 100 patients treated in the quarter. The company also announced a strategic restructuring to extend its cash runway into Q4 2026 and reiterated its full-year 2025 total product revenue guidance.

Iovance Biotherapeutics reported total product revenue of $49.3 million for the first quarter of 2025, primarily driven by Amtagvi sales. The company experienced a net loss of $116.2 million, or $0.36 per share. The revenue was impacted by a reduction in capacity due to scheduled maintenance at their manufacturing facility, but full production has resumed.

Iovance Biotherapeutics successfully drove strong early adoption for its U.S. commercial launch of Amtagvi®, achieving the upper end of its FY24 guidance range. The company reported total product revenue of $73.7 million for Q4 2024 and $164.1 million for FY24, with significant growth in Amtagvi and Proleukin sales. Net loss for Q4 2024 was $78.6 million, a notable improvement from the previous year.

Iovance Biotherapeutics reported a net loss of $83.5 million for Q3 2024, with revenue of $58.6 million driven by Amtagvi and Proleukin sales. The company's cash position as of September 30, 2024, was approximately $403.8 million, expected to fund operations into early 2026.

Iovance Biotherapeutics reported a revenue of $31.1 million for Q2 2024, driven by the launch of Amtagvi and continued Proleukin sales. The company's cash position as of July 24, 2024, is approximately $449.6 million, expected to fund operations into early 2026.

Iovance Biotherapeutics reported a net loss of $113.0 million for the first quarter of 2024, with revenue of $0.7 million from Proleukin sales. The company highlighted the strong initial demand for Amtagvi, with over 100 patients enrolled across more than 40 authorized treatment centers.

Iovance Biotherapeutics reported fourth quarter 2023 financial results, featuring a net loss of $116.4 million, or $0.45 per share, and revenue of $0.5 million from Proleukin® sales following its acquisition in May 2023. The company's cash position is expected to fund operations well into the second half of 2025, with the U.S. launch of Amtagvi™ underway and regulatory submissions planned in Europe, the UK, and Canada.

Iovance Biotherapeutics reported a net loss of $113.8 million for the third quarter of 2023, with revenue of $0.5 million from Proleukin® sales. The company's cash, cash equivalents, investments and restricted cash totaled $427.8 million as of September 30, 2023, which is expected to fund operations into 2025.

Iovance reported a net loss of $106.5 million for the second quarter of 2023. The company's cash, cash equivalents, investments and restricted cash totaled $317.3 million as of June 30, 2023. The Priority Review of their BLA for lifileucel in advanced melanoma remains on track with a PDUFA action date of November 25, 2023.

Iovance Biotherapeutics reported a net loss of $107.4 million, or $0.50 per share, for the first quarter ended March 31, 2023. The company's cash, cash equivalents, investments and restricted cash totaled $632.7 million at March 31, 2023. They expect the cash position is sufficient to fund operations into the second half of 2024.

Iovance Biotherapeutics reported a net loss for the fourth quarter ended December 31, 2022, was $105.3 million, or $0.64 per share. The company had $478.3 million in cash, cash equivalents, investments and restricted cash at December 31, 2022. They raised approximately $450.0 million during the fourth quarter of 2022 and first quarter of 2023 to date.

Iovance Biotherapeutics reported a net loss for the third quarter ended September 30, 2022, of $99.6 million, or $0.63 per share, with research and development expenses at $72.5 million and general and administrative expenses at $27.9 million. The company had $366.6 million in cash, cash equivalents, investments and restricted cash at September 30, 2022, which is expected to fund operations into 2024.

Iovance reported a net loss of $99.3 million, or $0.63 per share, for the second quarter ended June 30, 2022. The company had $430.9 million in cash, cash equivalents, investments and restricted cash at June 30, 2022, which is expected to fund operations into 2024. The BLA submission for lifileucel in metastatic melanoma is on track for August 2022.

Iovance Biotherapeutics reported a net loss of $91.6 million for the first quarter of 2022, with research and development expenses increasing to $68.3 million and general and administrative expenses rising to $23.4 million. The company's cash, cash equivalents, investments, and restricted cash totaled $516.0 million as of March 31, 2022, expected to fund operations into 2024.

Iovance Biotherapeutics reported a net loss of $99.3 million for the fourth quarter of 2021, with research and development expenses at $75.6 million and general and administrative expenses at $23.8 million. The company's cash position at the end of 2021 was $602.1 million, expected to fund operations into 2024.

Iovance Biotherapeutics reported a net loss of $86.1 million, or $0.55 per share, for the third quarter ended September 30, 2021. The company had $660.8 million in cash, cash equivalents, investments and restricted cash at September 30, 2021. They are focused on addressing FDA feedback regarding potency assays for lifileucel to support their planned BLA submission.

Iovance Biotherapeutics reported a net loss of $81.4 million, or $0.53 per share, for the second quarter ended June 30, 2021. The company held $708.7 million in cash, cash equivalents, investments and restricted cash at June 30, 2021. Research and development expenses were $62.1 million, and general and administrative expenses were $19.3 million for the quarter.

Iovance Biotherapeutics reported its first quarter 2021 financial results, highlighting a net loss of $75.4 million, or $0.51 per share, and holding $610.2 million in cash, cash equivalents, investments and restricted cash.

Iovance Biotherapeutics reported a net loss for the fourth quarter of 2020 of $68.4 million, or $0.47 per share, and held $635.0 million in cash, cash equivalents, short-term investments, and restricted cash at the end of the year. The company anticipates its cash balance will be sufficient into 2023.

Iovance Biotherapeutics reported a net loss of $58.6 million, or $0.40 per share, for the third quarter ended September 30, 2020. The company held $719.7 million in cash, cash equivalents, short-term investments and restricted cash at September 30, 2020.

Iovance Biotherapeutics reported a net loss of $63.0 million for the second quarter of 2020, with research and development expenses at $49.3 million and general and administrative expenses at $14.4 million. The company held $777.4 million in cash, cash equivalents, short-term investments, and restricted cash as of June 30, 2020.

Iovance Biotherapeutics reported a net loss of $69.6 million, or $0.55 per share, for the first quarter ended March 31, 2020. The company held $251.2 million in cash, cash equivalents, short-term investments and restricted cash at the end of the quarter.

Iovance Biotherapeutics reported a net loss for the fourth quarter ended December 31, 2019, was $63.6 million, or $0.50 per share, compared to a net loss of $32.6 million, or $0.27 per share, for the fourth quarter ended December 31, 2018.